ATE446972T1 - Il-1 bindende antikörper und fragmente davon - Google Patents
Il-1 bindende antikörper und fragmente davonInfo
- Publication number
- ATE446972T1 ATE446972T1 AT06773749T AT06773749T ATE446972T1 AT E446972 T1 ATE446972 T1 AT E446972T1 AT 06773749 T AT06773749 T AT 06773749T AT 06773749 T AT06773749 T AT 06773749T AT E446972 T1 ATE446972 T1 AT E446972T1
- Authority
- AT
- Austria
- Prior art keywords
- fragments
- binding antibodies
- seq
- amino acid
- acid sequence
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 2
- 108010002352 Interleukin-1 Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69283005P | 2005-06-21 | 2005-06-21 | |
| PCT/US2006/024261 WO2007002261A2 (en) | 2005-06-21 | 2006-06-21 | IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE446972T1 true ATE446972T1 (de) | 2009-11-15 |
Family
ID=37595818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06773749T ATE446972T1 (de) | 2005-06-21 | 2006-06-21 | Il-1 bindende antikörper und fragmente davon |
Country Status (23)
| Country | Link |
|---|---|
| US (11) | US7531166B2 (de) |
| EP (5) | EP1899378B1 (de) |
| JP (2) | JP4931919B2 (de) |
| KR (3) | KR101502920B1 (de) |
| CN (2) | CN101228188A (de) |
| AT (1) | ATE446972T1 (de) |
| AU (1) | AU2006262179B2 (de) |
| BR (1) | BRPI0612273C1 (de) |
| CA (2) | CA2612760C (de) |
| CY (3) | CY1109715T1 (de) |
| DE (1) | DE602006010072D1 (de) |
| DK (4) | DK2314623T3 (de) |
| ES (5) | ES2827247T3 (de) |
| HU (1) | HUE029021T2 (de) |
| IL (2) | IL188094A (de) |
| MX (2) | MX348154B (de) |
| NZ (1) | NZ565138A (de) |
| PL (4) | PL2322552T3 (de) |
| PT (3) | PT2314623E (de) |
| RU (1) | RU2518295C2 (de) |
| SI (4) | SI2314623T1 (de) |
| WO (1) | WO2007002261A2 (de) |
| ZA (1) | ZA200800555B (de) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101228188A (zh) * | 2005-06-21 | 2008-07-23 | 佐马技术有限公司 | IL-1β结合抗体及其片段 |
| PL2848258T3 (pl) | 2005-10-26 | 2018-06-29 | Novartis Ag | Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta |
| US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| CA2660519A1 (en) | 2006-08-10 | 2008-02-21 | Roy C. Levitt | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
| WO2008077145A2 (en) | 2006-12-20 | 2008-06-26 | Xoma Technology Ltd. | Treatment of il-1-beta related diseases |
| CA2839162A1 (en) * | 2006-12-20 | 2008-06-26 | Xoma Technology Ltd. | Methods for the treatment of il-1-.beta. related diseases |
| CA2993565C (en) * | 2007-05-29 | 2019-04-02 | Novartis Ag | New indications for anti-il-1-beta therapy |
| WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
| JP5536666B2 (ja) | 2007-12-20 | 2014-07-02 | ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー | 痛風の治療のための方法 |
| PL2293816T3 (pl) * | 2008-06-06 | 2013-04-30 | Xoma Us Llc | Sposoby leczenia reumatoidalnego zapalenia stawów |
| AU2009289547A1 (en) * | 2008-09-05 | 2010-03-11 | Xoma (Us) Llc | Methods for treating or preventing IL-1beta related diseases |
| EP3011953A1 (de) * | 2008-10-29 | 2016-04-27 | Ablynx N.V. | Stabilizierte formulierungen von einzeldomänen-antigen-bindenden molekülen |
| PE20120586A1 (es) * | 2009-01-29 | 2012-06-17 | Abbott Lab | Proteinas de union a il-1 |
| US10005830B2 (en) | 2009-03-05 | 2018-06-26 | Ablynx N.V. | Antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| JP2012526080A (ja) * | 2009-05-06 | 2012-10-25 | ノバルティス アーゲー | 抗IL1−β抗体の併用療法 |
| CN107243077A (zh) * | 2009-05-29 | 2017-10-13 | 爱克索马美国有限责任公司 | IL‑1β抗体及其结合片段的心血管相关用途 |
| US8389474B1 (en) * | 2009-07-14 | 2013-03-05 | Alan Anson Wanderer | Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion |
| PT2473528E (pt) * | 2009-09-03 | 2015-03-04 | Ablynx NV | Formulações estáveis de polipéptidos e seus usos |
| EP3187877A1 (de) | 2009-09-25 | 2017-07-05 | XOMA Technology Ltd. | Screening-verfahren |
| TW201124427A (en) * | 2009-10-15 | 2011-07-16 | Abbott Lab | IL-1 binding proteins |
| DE102009047243A1 (de) | 2009-11-27 | 2011-06-01 | Orgentec Diagnostika Gmbh | Monospezifische Polypeptidreagenzien |
| US8551487B2 (en) * | 2010-05-07 | 2013-10-08 | Xoma Technology, Ltd. | Methods for the treatment of IL-1β related conditions |
| NZ607510A (en) * | 2010-09-10 | 2014-10-31 | Apexigen Inc | Anti-il-1 beta antibodies and methods of use |
| JP5918275B2 (ja) * | 2011-02-08 | 2016-05-18 | アッヴィ・インコーポレイテッド | 変形性関節症及び疼痛の治療 |
| US20140308294A1 (en) | 2011-04-15 | 2014-10-16 | Merck Patent Gmbh | Anti-IL-1R1 Inhibitors For Use in Cancer |
| CN109276706A (zh) * | 2011-06-03 | 2019-01-29 | 麦瑟布莱斯特公司 | 治疗或预防神经性疾病的方法 |
| EP2731971A1 (de) | 2011-07-12 | 2014-05-21 | Universität Zürich | Modulatoren des nlrp3-inflammasome il-1ss-signalwegs zur vorbeugung und behandlung von akne |
| TWI461192B (zh) | 2011-07-20 | 2014-11-21 | Twi Biotechnology Inc | 降低血脂異常病患之糖化血色素的醫藥組成物 |
| DE102011083595A1 (de) * | 2011-09-28 | 2013-03-28 | Bayer Pharma AG | Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose |
| BR112014007253A2 (pt) | 2011-09-30 | 2017-03-28 | Novartis Ag | uso de anticorpos que se ligam a il-1beta |
| EP2794657B1 (de) * | 2011-12-19 | 2017-10-11 | Xoma (Us) Llc | Verfahren zur behandlung von akne |
| PL2623604T3 (pl) * | 2012-02-02 | 2015-07-31 | Baylor College Medicine | Biologiczny system dostarczania i ekspresji oparty na adenowirusie do zastosowania w leczeniu choroby zwyrodnieniowej stawów |
| CN105431452B (zh) | 2012-02-13 | 2019-12-31 | 新加坡科技研究局 | 中和IL-1β的人单克隆抗体 |
| JP6391574B2 (ja) * | 2012-08-31 | 2018-09-26 | アルゲン−エックス ビーブイビーエー | 種間標的内交差反応性を有する抗体分子を産生する方法 |
| WO2014068132A1 (en) | 2012-11-05 | 2014-05-08 | Delenex Therapeutics Ag | Binding members to il-1 beta |
| EP2931750B8 (de) | 2012-12-17 | 2021-11-03 | Cell Medica Inc. | Antikörper gegen il-1 beta |
| SI2956471T1 (sl) * | 2013-02-15 | 2024-06-28 | R-Pharm International, Llc | Sestava za zaviralca il-1beta in njegova uporaba |
| JP2016520615A (ja) * | 2013-05-31 | 2016-07-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | アルツハイマー病を処置するためのil−1アンタゴニストを使用する方法 |
| CN104341501B (zh) * | 2013-07-29 | 2019-08-30 | 上海睿智化学研究有限公司 | 抗IL-1β人源化单克隆抗体及其制备方法和应用 |
| CA3190793A1 (en) * | 2013-12-26 | 2015-07-02 | Mitsubishi Tanabe Pharma Corporation | Human anti-il-33 neutralizing monoclonal antibody |
| US12180264B2 (en) | 2014-03-24 | 2024-12-31 | R-Pharm Overseas, Inc. | IL1-R1 derived inhibitor of IL-1β and use thereof |
| WO2016008851A1 (en) * | 2014-07-14 | 2016-01-21 | Boehringer Ingelheim International Gmbh | Anti-il-1b antibodies |
| HK1245118A1 (zh) | 2015-05-18 | 2018-08-24 | Bayer Pharma Aktiengesellschaft | 选择性孕酮受体调节剂(sprm)方案 |
| JP6501650B2 (ja) * | 2015-06-25 | 2019-04-17 | 田辺三菱製薬株式会社 | ヒト抗il−33中和モノクローナル抗体 |
| EP3551047A1 (de) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Verfahren, vorrichtungen und systeme zur detektion des magen-darm-trakts |
| CN108218978B (zh) * | 2016-12-13 | 2020-05-12 | 沈阳何氏眼产业集团有限公司 | 一种重组白细胞介素18及其制备方法与应用 |
| WO2018112256A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| AU2018287519B2 (en) | 2017-06-22 | 2021-07-22 | Novartis Ag | IL-1beta binding antibodies for use in treating cancer |
| US20200158716A1 (en) * | 2017-07-17 | 2020-05-21 | Massachusetts Institute Of Technology | Cell atlas of healthy and diseased barrier tissues |
| CN115920031A (zh) | 2017-08-31 | 2023-04-07 | 田边三菱制药株式会社 | 含有il-33拮抗剂的子宫内膜异位症治疗剂 |
| KR20200052331A (ko) | 2017-09-13 | 2020-05-14 | 노파르티스 아게 | 알코올성 간염의 치료를 위한 il-1b 결합 항체의 용도 |
| AU2018368731A1 (en) | 2017-11-16 | 2020-05-14 | Novartis Ag | Combination therapies |
| GB2575853A (en) * | 2018-07-25 | 2020-01-29 | Robert Wotherspoon Hugh | IL-1ß binding antibody |
| US12403181B2 (en) | 2018-08-13 | 2025-09-02 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| WO2020039401A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | Treatment comprising il-1βeta binding antibodies and combinations thereof |
| CN116726362A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| EP3897613A1 (de) | 2018-12-21 | 2021-10-27 | Novartis AG | Verwendung von il-1beta-bindenden antikörpern |
| US20220356240A1 (en) * | 2019-09-26 | 2022-11-10 | Beth Israel Deaconess Medical Center, Inc. | Anti-inflammatory therapy in arrhythmogenic cardiomyopathy (acm) |
| US20230020548A1 (en) | 2019-12-09 | 2023-01-19 | Novartis Ag | Anti-interleukin 1 beta antibodies for treatment of sickle cell disease |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| MX2022007759A (es) | 2019-12-20 | 2022-07-19 | Novartis Ag | Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico. |
| TWI793503B (zh) * | 2020-01-20 | 2023-02-21 | 美商美國禮來大藥廠 | 抗IL-1β抗體 |
| JP7697695B2 (ja) * | 2020-01-21 | 2025-06-24 | タボテック バイオテクノロジー(チャンスー)カンパニー リミテッド | IL-1β受容体シグナル伝達に干渉する剤 |
| WO2022167916A1 (en) | 2021-02-03 | 2022-08-11 | Novartis Ag | Use of il-1b binding antibodies for treating neuroinflammatory disorders |
| CN114524875B (zh) * | 2021-11-11 | 2023-07-25 | 江苏莱森生物科技研究院有限公司 | 偶联IL-1β单克隆抗体的纳米硅球及应用 |
| WO2024258943A1 (en) * | 2023-06-13 | 2024-12-19 | Merck Sharp & Dohme Llc | Methods of using cyclic peptides for trapping interleukin-1 beta |
| CN116832720B (zh) * | 2023-06-19 | 2025-11-21 | 广州聚焦生物科技有限公司 | 一种发光免疫检测的冻干微球及其制备方法 |
| WO2025147631A1 (en) * | 2024-01-04 | 2025-07-10 | William Marsh Rice University | Encapsulated cells for the treatment of respiratory diseases and disorders |
Family Cites Families (152)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US493543A (en) * | 1893-03-14 | Lap-ring | ||
| US3887699A (en) | 1969-03-24 | 1975-06-03 | Seymour Yolles | Biodegradable polymeric article for dispensing drugs |
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| EP0052322B1 (de) | 1980-11-10 | 1985-03-27 | Gersonde, Klaus, Prof. Dr. | Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3483949D1 (de) | 1983-09-26 | 1991-02-21 | Udo Dr Med Ehrenfeld | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
| EP0143949B1 (de) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmazeutische Zusammensetzung mit Gehalt an Urokinase |
| DE3413608A1 (de) | 1984-04-11 | 1985-10-24 | Hoechst Ag, 6230 Frankfurt | Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung |
| US4762914A (en) | 1984-05-18 | 1988-08-09 | Auron Philip E | Truncated protein of interleukin-1 |
| DE3588241T2 (de) | 1984-05-18 | 2002-12-05 | Massachusetts Institute Of Technology, Cambridge | Menschliche IL-1 cDNS-Sequenzen die für biologisch aktive menschliche IL-1-Proteine kodieren |
| EP0569687B1 (de) | 1984-05-18 | 2002-08-21 | New England Medical Center Hospitals, Inc. | Menschliche IL-1 cDNS-Sequenzen die für biologisch aktive menschliche IL-1-Proteine kodieren |
| US5077219A (en) | 1984-05-18 | 1991-12-31 | New England Medical Center Hospitals | Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins |
| US5484887A (en) | 1984-06-19 | 1996-01-16 | Immunex Corporation | Homogeneous interleukin 1 |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5122459A (en) | 1984-12-31 | 1992-06-16 | Immunex Corporation | Gene encoding biologically active human interleukin 1 |
| US4772685A (en) | 1985-10-02 | 1988-09-20 | Merck & Co., Inc. | Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies |
| US4935343A (en) * | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| DK590387A (da) | 1986-11-13 | 1988-05-14 | Otsuka Pharma Co Ltd | Antistoffer mod interleukin-1 |
| US5474899A (en) | 1987-05-13 | 1995-12-12 | Cistron Biotechnology, Inc. | Selective immunoassay for IL-1 β |
| US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US5077218A (en) * | 1988-05-05 | 1991-12-31 | Oregon Lions Sight And Hearing Foundation Inc. | Eye transport apparatus |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| DE68925935T2 (de) | 1988-10-01 | 1996-08-14 | Otsuka Pharma Co Ltd | Antikörper gegen Interleukin-1-beta |
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| DE69032251T2 (de) | 1989-02-27 | 1998-08-13 | Massachusetts Institute Of Technology, Cambridge, Mass. | Il-1, dessen biologische aktivität inhibiert ist |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| JP2877509B2 (ja) | 1989-05-19 | 1999-03-31 | アムジエン・インコーポレーテツド | メタロプロテイナーゼ阻害剤 |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| JPH06506105A (ja) | 1990-08-29 | 1994-07-14 | ファーミング ビーブイ | 哺乳動物細胞における相同性組換え |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| IT1247472B (it) | 1991-05-31 | 1994-12-17 | Fidia Spa | Processo per la preparazione di microsfere contenenti componenti biologicamente attivi. |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| WO1994000470A1 (en) * | 1992-06-30 | 1994-01-06 | The Wistar Institute Of Anatomy And Biology | DEVELOPMENTAL EMBRYONIC MOUSE cDNA LIBRARIES |
| US6664114B1 (en) | 1992-08-03 | 2003-12-16 | Sapidyne Instruments, Inc. | Solid phase assay for detection of ligands |
| ES2151541T3 (es) | 1992-12-02 | 2001-01-01 | Alkermes Inc | Microesferas que contienen hormona del crecimiento de liberacion prolongada. |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
| US5959085A (en) | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6395547B1 (en) | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US6372716B1 (en) | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
| BR9509201A (pt) | 1994-09-09 | 1997-12-30 | Takeda Chemical Industries Ltd | Preparação de liberação sustemtada uso de um sal de metal polivalente insolúvel em água ou ligeiramente solúvel em água e processo para produzir uma preparação de liberação sustentada |
| WO1996012792A1 (en) * | 1994-10-20 | 1996-05-02 | Merck & Co., Inc. | INTERLEUKIN-1β DEFICIENT TRANSGENIC ANIMALS |
| WO1996012503A1 (en) * | 1994-10-21 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Remedy for diseases caused by il-6 production |
| CA2216919C (en) | 1995-03-28 | 2007-09-18 | Fidia Advanced Biopolymers Srl | Nanospheres comprising a biocompatible polysaccharide |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5817476A (en) | 1995-06-07 | 1998-10-06 | Genetics Institute, Inc. | Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins |
| EP0831787B1 (de) | 1995-06-07 | 2001-08-22 | Alkermes Controlled Therapeutics, Inc. | Mittel zur verzögerten freisetzung von menschlichem wachstumshormon |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
| US6168919B1 (en) | 1996-07-17 | 2001-01-02 | Diversa Corporation | Screening methods for enzymes and enzyme kits |
| US6455254B1 (en) | 1995-07-18 | 2002-09-24 | Diversa Corporation | Sequence based screening |
| US6004788A (en) | 1995-07-18 | 1999-12-21 | Diversa Corporation | Enzyme kits and libraries |
| US6030779A (en) | 1995-07-18 | 2000-02-29 | Diversa Corporation | Screening for novel bioactivities |
| US6057103A (en) | 1995-07-18 | 2000-05-02 | Diversa Corporation | Screening for novel bioactivities |
| US5958672A (en) | 1995-07-18 | 1999-09-28 | Diversa Corporation | Protein activity screening of clones having DNA from uncultivated microorganisms |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6238884B1 (en) | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
| US6740506B2 (en) | 1995-12-07 | 2004-05-25 | Diversa Corporation | End selection in directed evolution |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| US5965408A (en) | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
| US5830696A (en) | 1996-12-05 | 1998-11-03 | Diversa Corporation | Directed evolution of thermophilic enzymes |
| US6489145B1 (en) | 1996-07-09 | 2002-12-03 | Diversa Corporation | Method of DNA shuffling |
| US6713279B1 (en) | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
| US6358709B1 (en) | 1995-12-07 | 2002-03-19 | Diversa Corporation | End selection in directed evolution |
| US6352842B1 (en) | 1995-12-07 | 2002-03-05 | Diversa Corporation | Exonucease-mediated gene assembly in directed evolution |
| US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
| US6361974B1 (en) | 1995-12-07 | 2002-03-26 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
| US6562594B1 (en) | 1999-09-29 | 2003-05-13 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US6344328B1 (en) | 1995-12-07 | 2002-02-05 | Diversa Corporation | Method for screening for enzyme activity |
| US6764835B2 (en) | 1995-12-07 | 2004-07-20 | Diversa Corporation | Saturation mutageneis in directed evolution |
| US20030215798A1 (en) | 1997-06-16 | 2003-11-20 | Diversa Corporation | High throughput fluorescence-based screening for novel enzymes |
| US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US5939250A (en) | 1995-12-07 | 1999-08-17 | Diversa Corporation | Production of enzymes having desired activities by mutagenesis |
| US6368798B1 (en) | 1995-12-07 | 2002-04-09 | Diversa Corporation | Screening for novel bioactivities |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
| US5763239A (en) | 1996-06-18 | 1998-06-09 | Diversa Corporation | Production and use of normalized DNA libraries |
| US5770380A (en) | 1996-09-13 | 1998-06-23 | University Of Pittsburgh | Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold |
| UA70291C2 (en) * | 1996-10-31 | 2004-10-15 | Applied Research Systems | PEPTIDE CAPABLE OF BINDING TO INTERLEUKIN-1b-CONVEPEPTIDE CAPABLE OF BINDING TO INTERLEUKIN-1b-CONVERTING FERMENT (ICE) AND A PHARMACEUTICAL COMPOSITIRTING FERMENT (ICE) AND A PHARMACEUTICAL COMPOSITION CONTAINING IT ON CONTAINING IT |
| WO1998047921A1 (en) * | 1997-04-21 | 1998-10-29 | Schering Corporation | Mammalian cytokines; related reagents and methods |
| WO1999065927A2 (en) | 1998-06-17 | 1999-12-23 | Maxygen, Inc. | Method for producing polynucleotides with desired properties |
| US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6368861B1 (en) | 1999-01-19 | 2002-04-09 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| AU3391900A (en) | 1999-03-05 | 2000-09-21 | Maxygen, Inc. | Encryption of traits using split gene sequences |
| US6566329B1 (en) | 1999-06-28 | 2003-05-20 | Novo Nordisk A/S | Freeze-dried preparation of human growth hormone |
| US6475220B1 (en) | 1999-10-15 | 2002-11-05 | Whiteside Biomechanics, Inc. | Spinal cable system |
| GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| AU2001259758A1 (en) | 2000-05-12 | 2001-11-26 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
| GB0020685D0 (en) * | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| US20030026806A1 (en) | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
| US20030166069A1 (en) | 2000-11-28 | 2003-09-04 | Amgen, Inc. | Interleukin-1 receptor antagonist-like molecules and uses thereof |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US6864047B2 (en) * | 2001-03-29 | 2005-03-08 | Mayo Foundation For Medical Education And Research | IL1-β: a new target for myeloma therapy |
| US6727234B2 (en) | 2001-04-03 | 2004-04-27 | University Of Iowa Research Foundation | Isoprenoid analog compounds and methods of making and use thereof |
| AU2002355249A1 (en) * | 2001-07-26 | 2003-02-17 | Eli Lilly And Company | Interleukin-1 beta antibodies |
| JP4213586B2 (ja) | 2001-09-13 | 2009-01-21 | 株式会社抗体研究所 | ラクダ抗体ライブラリーの作製方法 |
| AU2002351505B2 (en) | 2001-10-19 | 2008-04-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders |
| US6673552B2 (en) | 2002-01-14 | 2004-01-06 | Diversa Corporation | Methods for purifying annealed double-stranded oligonucleotides lacking base pair mismatches or nucleotide gaps |
| EP1481010A2 (de) | 2002-02-28 | 2004-12-01 | Eli Lilly And Company | Anti-interleukin-1-beta-analoga |
| US7572770B2 (en) | 2002-06-27 | 2009-08-11 | University Of Zurich | Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes |
| WO2004009664A2 (en) | 2002-07-19 | 2004-01-29 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from |
| PL377091A1 (pl) | 2002-09-06 | 2006-01-23 | Amgen, Inc. | Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych |
| WO2004039834A2 (en) | 2002-11-01 | 2004-05-13 | Alk-Abelló A/S | Recombinant protein variants |
| WO2004067568A2 (en) * | 2003-01-24 | 2004-08-12 | Applied Molecular Evolution, Inc | Human il-1 beta antagonists |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| US20040266993A1 (en) | 2003-06-30 | 2004-12-30 | Evans Glen A. | Non-immunoglobulin binding polypeptides |
| US20050159590A1 (en) | 2003-08-25 | 2005-07-21 | Galit Rotman | Variants of interleukin-1 receptor antagonist: compositions and uses thereof |
| US20050152850A1 (en) | 2004-01-09 | 2005-07-14 | Engebretson Steven P. | Methods and compositions for facilitating metabolic control |
| US7732478B2 (en) | 2004-01-09 | 2010-06-08 | The Trustees Of Columbia University In The City Of New York | Methods for facilitating metabolic control |
| WO2005084696A1 (en) | 2004-03-08 | 2005-09-15 | Universita'degli Studi Di Milano | Methods and agents for controlling intestinal inflammation and mucosal immunity using agents interacting with tir8/sigirr |
| EP1576952A1 (de) | 2004-03-18 | 2005-09-21 | OctoPlus Technologies B.V. | Hydrogel-Mikrosphären mit verbessertem Freisetzungsprofil |
| US8618054B2 (en) | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| EP1851245B1 (de) | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antikörper gegen interleukin-1-beta |
| CN101228188A (zh) * | 2005-06-21 | 2008-07-23 | 佐马技术有限公司 | IL-1β结合抗体及其片段 |
| FR2895611B1 (fr) | 2005-12-23 | 2008-02-22 | Thales Sa | Architecture et procede pour controler le transfert d'informations entre utilisateurs |
| US8479265B2 (en) * | 2008-07-02 | 2013-07-02 | Oracle International Corporation | Usage based authorization |
-
2006
- 2006-06-21 CN CNA2006800265519A patent/CN101228188A/zh active Pending
- 2006-06-21 SI SI200631432T patent/SI2314623T1/sl unknown
- 2006-06-21 EP EP06773749A patent/EP1899378B1/de active Active
- 2006-06-21 EP EP10179089.7A patent/EP2322552B1/de active Active
- 2006-06-21 PT PT10179088T patent/PT2314623E/pt unknown
- 2006-06-21 KR KR1020137015781A patent/KR101502920B1/ko active Active
- 2006-06-21 PL PL10179089T patent/PL2322552T3/pl unknown
- 2006-06-21 MX MX2015004669A patent/MX348154B/es unknown
- 2006-06-21 EP EP10179088A patent/EP2314623B1/de active Active
- 2006-06-21 PT PT91741900T patent/PT2163562E/pt unknown
- 2006-06-21 AU AU2006262179A patent/AU2006262179B2/en active Active
- 2006-06-21 JP JP2008518374A patent/JP4931919B2/ja not_active Expired - Fee Related
- 2006-06-21 CA CA2612760A patent/CA2612760C/en active Active
- 2006-06-21 DE DE602006010072T patent/DE602006010072D1/de active Active
- 2006-06-21 AT AT06773749T patent/ATE446972T1/de active
- 2006-06-21 CA CA2873914A patent/CA2873914A1/en not_active Abandoned
- 2006-06-21 US US11/472,813 patent/US7531166B2/en active Active
- 2006-06-21 EP EP09174190.0A patent/EP2163562B1/de active Active
- 2006-06-21 WO PCT/US2006/024261 patent/WO2007002261A2/en not_active Ceased
- 2006-06-21 ES ES16154804T patent/ES2827247T3/es active Active
- 2006-06-21 CN CN201210157441.3A patent/CN102775493B/zh active Active
- 2006-06-21 ES ES06773749T patent/ES2335232T3/es active Active
- 2006-06-21 ES ES10179089.7T patent/ES2569917T3/es active Active
- 2006-06-21 DK DK10179088.9T patent/DK2314623T3/da active
- 2006-06-21 PL PL09174190T patent/PL2163562T3/pl unknown
- 2006-06-21 SI SI200630518T patent/SI1899378T1/sl unknown
- 2006-06-21 BR BRPI0612273A patent/BRPI0612273C1/pt active IP Right Grant
- 2006-06-21 HU HUE10179089A patent/HUE029021T2/en unknown
- 2006-06-21 SI SI200632052A patent/SI2322552T1/sl unknown
- 2006-06-21 DK DK06773749.4T patent/DK1899378T3/da active
- 2006-06-21 ES ES10179088T patent/ES2391334T3/es active Active
- 2006-06-21 PL PL06773749T patent/PL1899378T3/pl unknown
- 2006-06-21 ES ES09174190.0T patent/ES2439709T3/es active Active
- 2006-06-21 DK DK10179089.7T patent/DK2322552T3/en active
- 2006-06-21 EP EP16154804.5A patent/EP3056511B1/de not_active Not-in-force
- 2006-06-21 NZ NZ565138A patent/NZ565138A/en unknown
- 2006-06-21 RU RU2008102135/10A patent/RU2518295C2/ru active
- 2006-06-21 KR KR1020147030783A patent/KR20140139618A/ko not_active Ceased
- 2006-06-21 SI SI200631713T patent/SI2163562T1/sl unknown
- 2006-06-21 PT PT06773749T patent/PT1899378E/pt unknown
- 2006-06-21 DK DK09174190.0T patent/DK2163562T3/da active
- 2006-06-21 MX MX2007016032A patent/MX2007016032A/es active IP Right Grant
- 2006-06-21 PL PL10179088T patent/PL2314623T3/pl unknown
- 2006-06-21 KR KR1020087001520A patent/KR101366450B1/ko not_active Expired - Fee Related
-
2007
- 2007-12-12 IL IL188094A patent/IL188094A/en active IP Right Grant
-
2008
- 2008-01-18 ZA ZA200800555A patent/ZA200800555B/xx unknown
- 2008-07-18 US US12/218,997 patent/US7695717B2/en active Active
- 2008-07-18 US US12/218,914 patent/US7582742B2/en active Active
-
2009
- 2009-05-11 US US12/463,844 patent/US7744866B2/en active Active
- 2009-05-11 US US12/464,006 patent/US7829093B2/en active Active
- 2009-05-11 US US12/463,741 patent/US7744865B2/en active Active
- 2009-05-11 US US12/464,061 patent/US7829094B2/en active Active
- 2009-05-12 US US12/464,381 patent/US7943121B2/en active Active
- 2009-05-12 US US12/464,323 patent/US7988968B2/en active Active
- 2009-12-09 IL IL202630A patent/IL202630A/en active IP Right Grant
-
2010
- 2010-01-05 CY CY20101100017T patent/CY1109715T1/el unknown
-
2011
- 2011-05-17 US US13/109,680 patent/US8377442B2/en active Active
- 2011-08-23 JP JP2011181463A patent/JP2011254835A/ja active Pending
-
2012
- 2012-09-28 CY CY20121100891T patent/CY1113153T1/el unknown
-
2013
- 2013-01-11 US US13/739,707 patent/US9206252B2/en active Active
- 2013-12-16 CY CY20131101132T patent/CY1114851T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE446972T1 (de) | Il-1 bindende antikörper und fragmente davon | |
| CY1119650T1 (el) | Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| NZ596295A (en) | Anti-5T4 antibodies and uses thereof | |
| DK1706424T3 (da) | FC-region varianter | |
| DK1392359T3 (da) | Specifikke bindingsproteiner og deres anvendelser | |
| CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| RU2017124859A (ru) | Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты | |
| CY1110877T1 (el) | Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση | |
| WO2006113546A3 (en) | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers | |
| ATE368688T1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
| IS8016A (is) | Prótín sem bindast viðtaka NOGO | |
| EA200600042A1 (ru) | Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах | |
| EP3300739A3 (de) | An 161p2f10b-proteine bindende antikörper und zugehörige moleküle | |
| ATE449177T1 (de) | Staphylococcus epidermidis antigene | |
| EP2098594A4 (de) | Nukleinsäuremolekül mit fähigkeit zur bindung an aus kaninchen stammenden igg-antikörper | |
| CY1117395T1 (el) | Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1899378 Country of ref document: EP |
|
| EEIH | Change in the person of patent owner |